Literature DB >> 15712191

Erythropoietin and erythropoietin receptor system in a large uterine myoma of a patient with myomatous erythrocytosis syndrome: possible relationship with the pathogenesis of unusual tumor size.

Fabrizio Pollio1, Stefania Staibano, Gelsomina Mansueto, Gaetano De Rosa, Francesco Persico, Marianna De Falco, Andrea Di Lieto.   

Abstract

The rare condition of women with erythrocytosis and a concurrent myomatous uterus has been classified as "myomatous erythrocytosis syndrome". Substantial myoma size has been noted as a common denominator in this condition in which recent evidence have confirmed erythropoietin (Epo) production by myoma tissues themselves. Apart from its primary endocrine role in controlling erythropoiesis, Epo has been demonstrated to mediate several cellular processes such as angiogenesis, mitogenesis, and inhibition of apoptosis by autocrine and paracrine mechanisms. Recently, Epo and its receptor (Epo-R) have been shown to be involved in the growth, viability, and angiogenesis of several malignant tumors including human female reproductive organ malignancies. In this paper, we researched on Epo and, as a first in the literature, Epo-R immunoexpression in a large uterine myoma of a term pregnant patient suffering from the myomatous erythrocytosis syndrome. Eight nongravidic leiomyomas and 8 gravidic leiomyomas were used as control group samples. Apart from confirming Epo production by myoma smooth muscle cells in the myomatous erythrocytosis syndrome, we reveal in this pathologic condition a characteristic strong Epo-R expression in myoma endothelial cells and a weak and sporadic Epo-R expression in myoma smooth muscle cells. The striking presence of Epo-R within myoma tissues in the case of the myomatous erythrocytosis syndrome allows us to speculate that myoma Epo production, besides determining erythrocytosis through systemic effects, may contribute, acting by autocrine and paracrine mechanisms, in determining the large myoma size almost always observed in this condition. Finally, we confirm a less but specific immunostaining for Epo in uterine myomas of patients without erythrocytosis and, as a first in the literature, we prove a weak and sporadic Epo-R expression in these lesions. These last results may contribute to knowledge of the yet unclear etiopathogenesis of the most common human gynecologic neoplasm.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15712191     DOI: 10.1016/j.humpath.2004.10.009

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  6 in total

1.  Core erythropoietin receptor signals for late erythroblast development.

Authors:  Madhu P Menon; Jing Fang; Don M Wojchowski
Journal:  Blood       Date:  2005-12-06       Impact factor: 22.113

2.  Myomatous erythrocytosis syndrome: A case report.

Authors:  Xin-Yu Shu; Na Chen; Bi-Yun Chen; Hui-Xia Yang; Hui Bi
Journal:  World J Clin Cases       Date:  2022-04-06       Impact factor: 1.534

3.  Expression of platelet-derived growth factor BB, erythropoietin and erythropoietin receptor in canine and feline osteosarcoma.

Authors:  F R L Meyer; R Steinborn; H Grausgruber; B Wolfesberger; I Walter
Journal:  Vet J       Date:  2015-06-06       Impact factor: 2.688

4.  Extramedullary hematopoiesis in uterine leiomyoma associated with numerous intravascular thrombi.

Authors:  Xiaoyan Cui; Deniz Peker; Heather O Greer; Michael G Conner; Lea Novak
Journal:  Case Rep Pathol       Date:  2014-03-06

5.  Myomatous erythrocytosis syndrome: A case series.

Authors:  Glaiza S de Guzman; Eileen M Manalo
Journal:  Case Rep Womens Health       Date:  2019-08-21

6.  Myomatous Erythrocytosis Syndrome: Case Report and Review of the Literature.

Authors:  Pooja Suresh; Sanaa Rizk
Journal:  Cureus       Date:  2020-02-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.